Kestra Medical Technologies, LTD. (KMTS) — SEC Filings

Overview

Kestra Medical Technologies, LTD. (KMTS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-3ASR filed on Apr 1, 2026: Kestra Medical Technologies, Ltd. filed an S-3ASR on April 1, 2026, for an automatic shelf registration statement. This filing allows the company to register securities for future sale without needing to file a new registration statement each time. The company is in the Surgical & Medical Instrument

Sentiment Summary

Across 18 filings, the sentiment breakdown is: 15 neutral, 3 mixed. The dominant filing sentiment for Kestra Medical Technologies, LTD. is neutral.

Filing Type Overview

Kestra Medical Technologies, LTD. (KMTS) has filed 1 S-3ASR, 3 10-Q, 9 8-K, 1 DEF 14A, 1 10-K, 2 S-1/A, 1 S-1 with the SEC between Feb 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (18)

• Kestra Medical Technologies Files S-3ASR — S-3ASR · Apr 1, 2026 Risk: medium
  Kestra Medical Technologies, Ltd. filed an S-3ASR on April 1, 2026, for an automatic shelf registration statement. This filing allows the company to register se
• Kestra Medical Technologies' Losses Widen Despite Revenue Surge — 10-Q · Dec 11, 2025 Risk: high
  Kestra Medical Technologies, Ltd. (KMTS) reported a significant increase in revenue for the three months ended October 31, 2025, reaching $22.565 million, up fr
• Kestra Medical Technologies Files 8-K for Material Agreement — 8-K · Dec 4, 2025 Risk: medium
  Kestra Medical Technologies, Ltd. filed an 8-K on December 4, 2025, reporting a material definitive agreement entered into on December 2, 2025. The filing also
• 8-K Filing — 8-K · Dec 1, 2025
• Kestra Medical Technologies Files 8-K — 8-K · Nov 10, 2025 Risk: low
  Kestra Medical Technologies, Ltd. filed an 8-K on November 10, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, he
• Kestra Medical Technologies' Revenue Soars 51.5%, Net Loss Widens — 10-Q · Sep 12, 2025 Risk: high
  Kestra Medical Technologies, Ltd. (KMTS) reported a significant increase in revenue for the three months ended July 31, 2025, reaching $19.371 million, up from
• Kestra Medical Technologies Files 8-K — 8-K · Sep 11, 2025 Risk: low
  Kestra Medical Technologies, Ltd. filed an 8-K on September 11, 2025, reporting on its Results of Operations and Financial Condition, and including Financial St
• Kestra Medical Technologies Files 8-K on Security Holder Vote — 8-K · Sep 4, 2025 Risk: medium
  Kestra Medical Technologies, Ltd. filed an 8-K on September 4, 2025, reporting on a matter submitted to a vote of its security holders on September 3, 2025. The
• Kestra Medical Tech Sets Sept. 3 Shareholder Meeting for Key Votes — DEF 14A · Jul 22, 2025 Risk: low
  Kestra Medical Technologies, Ltd. (KMTS) is holding its 2025 Annual General Meeting of Shareholders on September 3, 2025, to address key corporate governance an
• Kestra Medical Goes Public, Secures $100M+ Loan for Growth — 10-K · Jul 17, 2025 Risk: high
  Kestra Medical Technologies, Ltd. (KMTS) reported a significant strategic shift with its IPO on March 14, 2025, issuing common stock. The company also secured s
• Kestra Medical Technologies Files 8-K on Financials — 8-K · Jul 15, 2025 Risk: low
  Kestra Medical Technologies, Ltd. filed an 8-K on July 15, 2025, reporting on its Results of Operations and Financial Condition. The filing includes financial s
• Kestra Medical Technologies Reports Officer/Director Changes — 8-K · Jun 6, 2025 Risk: medium
  Kestra Medical Technologies, Ltd. filed an 8-K on June 6, 2025, reporting events as of June 4, 2025. The filing indicates changes related to the departure of di
• Kestra Medical Technologies Files 10-Q for Jan 31, 2025 — 10-Q · Apr 17, 2025 Risk: medium
  Kestra Medical Technologies, Ltd. filed its 10-Q for the period ending January 31, 2025. The filing details financial performance and operational updates. Key f
• Kestra Medical Technologies Files 8-K on Financials — 8-K · Apr 14, 2025 Risk: low
  Kestra Medical Technologies, Ltd. filed an 8-K on April 14, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statement
• Kestra Medical Technologies Reports Material Events — 8-K · Mar 7, 2025 Risk: medium
  Kestra Medical Technologies, Ltd. filed an 8-K on March 7, 2025, reporting several material events as of March 5, 2025. These include entering into a material d
• Kestra Medical Technologies Files IPO Amendment — S-1/A · Mar 3, 2025 Risk: medium
  Kestra Medical Technologies, Ltd. filed an S-1/A amendment on March 3, 2025, for its initial public offering. The company, incorporated in Bermuda with principa
• Kestra Medical Technologies Files IPO Amendment — S-1/A · Feb 26, 2025 Risk: medium
  Kestra Medical Technologies, Ltd. filed an S-1/A amendment on February 26, 2025, for its initial public offering. The company, incorporated in Bermuda with prin
• Kestra Medical Technologies Files for IPO — S-1 · Feb 10, 2025 Risk: medium
  Kestra Medical Technologies, Ltd. filed an S-1 registration statement with the SEC on February 10, 2025, indicating its intent to go public. The company, headqu

Risk Profile

Risk Assessment: Of KMTS's 17 recent filings, 3 were flagged as high-risk, 9 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Kestra Medical Technologies, LTD.'s most recent 10-Q filing (Dec 11, 2025):

• Revenue: $41.937M
• Net Income: -$58.611M
• EPS: -$0.64
• Debt-to-Equity: 0.50
• Cash Position: $175.424M
• Operating Margin: -144.6%
• Total Assets: $246.701M
• Total Debt: $41.873M

Key Executives

• Kirkland, WA
• Bermuda
• Brian Webster
• Christie W.S. Mok
• Sophia Hudson

Industry Context

Kestra operates in the dynamic medical technologies sector, characterized by rapid innovation, significant R&D investment, and a complex regulatory environment. The industry faces intense competition from both established global players and agile startups. Trends include the increasing adoption of minimally invasive devices, digital health solutions, and personalized medicine, all requiring substantial capital for development and market penetration.

Top Tags

medical-devices (6) · Medical Devices (3) · IPO (3) · ipo (3) · sec-filing (3) · Wearable Defibrillator (2) · Revenue Growth (2) · Net Loss (2) · Cash Burn (2) · material-agreement (2)

Key Numbers

• Revenue: $41.937M — Increased 52.5% for the six months ended October 31, 2025, from $27.492M in 2024.
• Net Loss: $58.611M — Widened for the six months ended October 31, 2025, from $40.944M in 2024.
• Selling, General and Administrative Expenses: $72.029M — Increased significantly for the six months ended October 31, 2025, from $40.682M in 2024.
• Net Cash Used in Operating Activities: $44.617M — Increased for the six months ended October 31, 2025, from $35.555M in 2024.
• Cash and Cash Equivalents: $175.424M — Decreased from $237.595M at April 30, 2025, indicating significant cash burn.
• Accumulated Deficit: $578.860M — Increased as of October 31, 2025, from $520.249M at April 30, 2025.
• Common Shares Outstanding: 51,449,053 — As of October 31, 2025, reflecting recent warrant exercises and IPO.
• IPO Proceeds: $215.789M — Raised in March 2025, after deducting underwriting discounts and commissions.
• Quarterly Revenue Growth: 53.4% — Increase in revenue for the three months ended October 31, 2025, compared to 2024.
• Net Loss Per Share: $0.64 — For the three months ended October 31, 2025, compared to $1.19 in 2024 (adjusted).
• SEC File Number: 001-42549 — Identifies the company's filing history with the SEC.
• Cash Used in Operating Activities: $26.274M — For the three months ended July 31, 2025, up from $17.499M in Q3 2024
• Number of Class I directors to be elected: 2 — These directors will serve until the 2028 annual meeting.
• Year of the Employee Stock Purchase Plan: 2025 — Shareholders will vote to approve the Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan.
• Fiscal year for auditor appointment: 2026 — PricewaterhouseCoopers LLP is to be ratified for the fiscal year ending April 30, 2026.

Frequently Asked Questions